Search Results

There are 4961 results for: content related to: Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

  1. Natalizumab for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald and John WD McDonald

    Published Online : 24 JAN 2007, DOI: 10.1002/14651858.CD006097.pub2

  2. Natalizumab for relapsing remitting multiple sclerosis

    Intervention Review

    The Cochrane Library

    Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj and Ian Galea

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD007621.pub2

  3. You have full text access to this OnlineOpen article
    Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 4, April 2015, Pages: 373–387, Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael Barnett, Maria Trojano, Helmut Butzkueven and on behalf of the MSBase Investigators and the TOP investigators

    Version of Record online : 27 FEB 2015, DOI: 10.1002/acn3.180

  4. You have free access to this content
    Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

    Intervention Review

    The Cochrane Library

    Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher and Georgia Salanti

    Published Online : 6 JUN 2013, DOI: 10.1002/14651858.CD008933.pub2

  5. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

    Inflammatory Bowel Diseases

    Volume 13, Issue 1, January 2007, Pages: 2–11, Bruce E. Sands, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton and Stephen B. Hanauer

    Version of Record online : 19 DEC 2006, DOI: 10.1002/ibd.20014

  6. You have free access to this content
    Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

    CNS Drug Reviews

    Volume 13, Issue 1, March 2007, Pages: 79–95, Olaf Stüve and Jeffrey L. Bennett

    Version of Record online : 24 APR 2007, DOI: 10.1111/j.1527-3458.2007.00003.x

  7. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2203–2208, S.V. Kane, S. Horst, W.J. Sandborn, B. Becker, B. Neis, M. Moscandrew, K.A. Hanson, W.J. Tremaine, D.H. Bruining, W.A. Faubion, D.S. Pardi, W.S. Harmsen, A.R. Zinsmeister and E.V. Loftus

    Version of Record online : 14 MAR 2012, DOI: 10.1002/ibd.22943

  8. You have full text access to this OnlineOpen article
    Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 1, January 2015, Pages: 43–55, Jens Ingwersen, Til Menge, Britta Wingerath, Derya Kaya, Jonas Graf, Tim Prozorovski, Andreas Keller, Christina Backes, Markus Beier, Matthias Scheffler, Thomas Dehmel, Bernd C. Kieseier, Hans-Peter Hartung, Patrick Küry and Orhan Aktas

    Version of Record online : 5 DEC 2014, DOI: 10.1002/acn3.152

  9. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 144–156, Nancy G. Wehner, George Shopp, Ingrid Osterburg, Antje Fuchs, Eberhard Buse and Janet Clarke

    Version of Record online : 12 MAR 2009, DOI: 10.1002/bdrb.20193

  10. You have free access to this content
    Clinically significant liver injury in patients treated with natalizumab

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 9, May 2010, Pages: 1028–1035, S. BEZABEH, C. M. FLOWERS, C. KORTEPETER and M. AVIGAN

    Version of Record online : 16 FEB 2010, DOI: 10.1111/j.1365-2036.2010.04262.x

  11. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

    Annals of Neurology

    Volume 77, Issue 3, March 2015, Pages: 425–435, Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson, Celia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Gabor Rum, Cavit Boz, Eva Havrdova, Helmut Butzkueven and on behalf of the MSBase Study Group

    Version of Record online : 17 JAN 2015, DOI: 10.1002/ana.24339

  12. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 117–130, Nancy G. Wehner, George Shopp, Satoru Oneda and Janet Clarke

    Version of Record online : 10 MAR 2009, DOI: 10.1002/bdrb.20190

  13. What to expect after natalizumab cessation in a real-life setting

    Acta Neurologica Scandinavica

    Volume 130, Issue 2, August 2014, Pages: 97–102, S. Salhofer-Polanyi, A. Baumgartner, J. Kraus, E. Maida, M. Schmied and F. Leutmezer, The Austrian Tysabri Registry Group

    Version of Record online : 10 APR 2014, DOI: 10.1111/ane.12250

  14. You have free access to this content
    Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model

    Neuropathology and Applied Neurobiology

    Volume 41, Issue 6, October 2015, Pages: 814–831, Darius Häusler, Stefan Nessler, Niels Kruse, Wolfgang Brück and Imke Metz

    Version of Record online : 2 MAY 2015, DOI: 10.1111/nan.12220

  15. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries

    European Journal of Neurology

    Volume 17, Issue 1, January 2010, Pages: 31–37, N. Putzki, O. Yaldizli, M. Mäurer, S. Cursiefen, S. Kuckert, C. Klawe, M. Maschke, B. Tettenborn and V. Limmroth

    Version of Record online : 9 JUL 2009, DOI: 10.1111/j.1468-1331.2009.02728.x

  16. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years

    European Journal of Neurology

    Volume 23, Issue 6, June 2016, Pages: 1101–1109, R. Zivadinov, D. Hojnacki, N. Bergsland, C. Kennedy, J. Hagemeier, R. Melia, D. P. Ramasamy, J. Durfee, E. Carl, M. G. Dwyer and B. Weinstock-Guttman

    Version of Record online : 21 MAR 2016, DOI: 10.1111/ene.12992

  17. You have free access to this content
    Monoclonal antibodies in treatment of multiple sclerosis

    Clinical & Experimental Immunology

    Volume 175, Issue 3, March 2014, Pages: 373–384, P. S. Rommer, A. Dudesek, O. Stüve and U.K. Zettl

    Version of Record online : 4 FEB 2014, DOI: 10.1111/cei.12197

  18. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

    European Journal of Neurology

    Volume 19, Issue 5, May 2012, Pages: 783–787, G. Borriello, L. Prosperini, C. Mancinelli, C. Giannì, F. Fubelli and C. Pozzilli

    Version of Record online : 7 NOV 2011, DOI: 10.1111/j.1468-1331.2011.03577.x

  19. You have full text access to this OnlineOpen article
    Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

    European Journal of Neurology

    Volume 21, Issue 3, March 2014, Pages: 377–e20, M. S. Freedman

    Version of Record online : 15 NOV 2013, DOI: 10.1111/ene.12299

  20. You have free access to this content
    The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

    British Journal of Haematology

    Volume 155, Issue 4, November 2011, Pages: 438–448, Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, Giovanni Tonon, Ursula Hainz, Yu-Tzu Tai, Sonia Vallet, Niels Halama, Dirk Jäger, Dian L. Olson, Martin Sattler, Dharminder Chauhan and Kenneth C. Anderson

    Version of Record online : 19 SEP 2011, DOI: 10.1111/j.1365-2141.2011.08864.x